Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
The Consortium of Multiple Sclerosis Centers has updated guidelines for using magnetic resonance imaging to evaluate people suspected of having multiple sclerosis.
Doctors use the MRI guidelines ... Read more
Genentech will present a host of new information on its multiple sclerosis treatment Ocrevus and lessons its scientists have learned about the disease at the 7th Joint ECTRIMS-ACTRIMS Meeting ... Read more
Aubagio (teriflunomide) may lead to reversible nail loss, researchers at Italy’s University of Bologna reported after reviewing the case of a 55-year-old woman with relapsing-remitting multiple sclerosis.
They described ... Read more
Magnetic resonance imaging (MRI) brain scans of children could reveal changes associated with multiple sclerosis (MS) before any symptoms are developed, according to a study by scientists ... Read more
Pain, walking problems and fatigue are factors that most strongly lower self-perceived health in multiple sclerosis, researchers at the New York University Langone Medical Center have found.
This ... Read more
Two short courses of Lemtrada prevented multiple sclerosis from becoming active and progressing for five years, a study reported.
Lemtrada’s maker, Sanofi-Genzyme, said the study covered the two-year CARE-MS ... Read more
A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, ... Read more
Behavioral therapy focusing on goal attainment might reduce cognitive fatigue in multiple sclerosis patients, finds a study that used brain imaging to examine goal-oriented tasks involving ... Read more
Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis and other neurodegenerative conditions.
The ... Read more
A European Patent Office decision has opened the door to Synthon providing cheaper generic versions of Teva Pharmaceutical’s Copaxone to people with relapsing multiple sclerosis.
What looks ... Read more
Patients with primary progressive multiple sclerosis have more severe cognitive impairment than those with relapsing-remitting multiple sclerosis, according to a German study that analyzed published data ... Read more
Autologous hematopoietic stem cell transplants for relapsing-remitting multiple sclerosis are superior to currently approved disease-modifying drugs, according to a Swedish study published in the Journal of ... Read more
A Phase 2b trial assessing the experimental retroviral-targeting treatment GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS) failed to meet its primary goal of reducing brain lesions ... Read more
The European Commission has approved Merck KGaA’s Mavenclad (cladribine tablets) to treat highly active relapsing forms of multiple sclerosis (MS). The Aug. 25 decision in Brussels marks the first ... Read more
Merck’s Mavenclad tablets significantly improve quality of life among relapsing multiple sclerosis patients while reducing the number of relapses, according to new analyses of previously unpublished ... Read more
Secondary progressive multiple sclerosis (SPMS) patients have larger quantities of certain antibodies to the stomach ulcer bacterium Helicobacter pylori than those with relapsing-remitting multiple sclerosis (RMSS), finds ... Read more
The European Medicines Agency has restricted the use of Zinbryta (daclizumab) for relapsing multiple sclerosis after reports of patients experiencing severe liver damage and one dying ... Read more
Pin It on Pinterest